Videos

Videos

FDA Approval Expands Isatuximab Delivery Options in Multiple Myeloma

08/07/2026

Sikander Ailawadhi, MD

Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...

Sikander Ailawadhi, MD,...

08/07/2026

Oncology

Videos

Subcutaneous Amivantamab Shows Promise in Previously Treated HPV-Negative Head and Neck Cancer

08/06/2026

Barbara Burtness, MD, FASCO

Barbara Burtness, MD, discusses results from cohort 1 of the phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in previously treated HPV-negative head and neck squamous cell carcinoma, highlighting encouraging response rates,...

Barbara Burtness, MD, discusses...

08/06/2026

Oncology

Videos

Testing Across the Patient Journey: Longitudinal Biomarker Strategy in NSCLC

08/05/2026

Jamie Chaft, MD

In this video, Jamie Chaft, MD, discusses why biomarker testing in NSCLC should be reassessed over time as clinical questions evolve across diagnosis, treatment response, progression, and later-line decision-making. She highlights the role of...

In this video, Jamie Chaft, MD,...

08/05/2026

Oncology

Videos

Not All MET Biomarkers Are the Same: Matching the Right Test to the Right Target

08/05/2026

Jamie Chaft, MD

In this video, Jamie Chaft, MD, explains why “MET-positive” is not a single biological category and why clinicians should distinguish among MET exon 14 skipping mutations, MET amplification, c-Met protein overexpression, and MET gene fusions....

In this video, Jamie Chaft, MD,...

08/05/2026

Oncology

Videos

The Tissue Journey in NSCLC: Why Testing Strategy Starts at Diagnosis

08/05/2026

Jamie Chaft, MD

In this video, Jamie Chaft, MD, discusses why tissue acquisition in NSCLC is more than a diagnostic step—it is the foundation for histologic classification, staging, and comprehensive biomarker testing. She highlights how upfront tissue...

In this video, Jamie Chaft, MD,...

08/05/2026

Oncology

Videos

How to Implement Subcutaneous Immunotherapy for Providers

07/30/2026

Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD

The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.

The panel outlines how to...

07/30/2026

Oncology

Videos

Advantages of Subcutaneous Immunotherapy for Patients 

07/30/2026

Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD

Experts and a patient discuss the practical advantages of subcutaneous immunotherapy for genitourinary cancers, including reduced chair time, less discomfort, and the resulting impact on patient quality of life and treatment burden.

Experts and a patient discuss...

07/30/2026

Oncology

Videos

Subcutaneous Immunotherapy Options Available for Genitourinary Cancer

07/30/2026

Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD

The panel reviews the clinical data behind subcutaneous pembrolizumab and nivolumab, comparing efficacy and pharmacokinetics to their IV counterparts, and shares early clinical impressions of introducing these formulations into practice.

The panel reviews the clinical...

07/30/2026

Oncology

Videos

Molecular Profiling Refines Prognosis and Treatment Selection in Low-Grade Glioma

07/28/2026

Brigitta Baumert, MD, PhD

Brigitta Baumert, MD, PhD, discusses long-term results from the phase 3 EORTC 22033-26033 trial comparing upfront radiotherapy with temozolomide in patients with clinically high-risk low-grade glioma, highlighting the prognostic value of...

Brigitta Baumert, MD, PhD,...

07/28/2026

Oncology

Videos

Early-Phase Immunotherapy Demonstrates Modest Activity in Recurrent or Metastatic Head and Neck Cancer

07/28/2026

Harold Nathan Tan, MD

Harold Nathan Tan, MD, discusses findings from a retrospective analysis of early-phase immunotherapy trials in recurrent or metastatic head and neck squamous cell carcinoma, highlighting the clinical activity of bispecific antibodies and the...

Harold Nathan Tan, MD, discusses...

07/28/2026

Oncology

Videos

Specialties

HMP Global Products

Events